Loading...
Please wait, while we are loading the content...
Similar Documents
Highlights of Prescribing Information Indication Starting Dose Dose Range Target Maintenance Dose* Full Prescribing Information: Contents* 1. Indications and Usage 1.1 Hypertension 1.2 Heart Failure 1.3 Post-myocardial Infarction 2. Dosage and Administration 2.1 Adult Hypertension 2.2 Pediatric Hype
| Content Provider | Semantic Scholar |
|---|---|
| Abstract | These highlights do not include all the information needed to use Diovan safely and effectively. See full prescribing information for Diovan. When pregnancy is detected, discontinue Diovan as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus (5.Diovan is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension (1.1) • Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2) • Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (1.3) Adult Hypertension (2.1) 80 or 160 mg once daily 80-320 mg once daily-Pediatric Hypertension (6 16 years) (2.1) 1.3 mg/kg once daily (up to 40 mg total) 1.3-2.7 mg/kg once daily (up to 40-160 mg total)-Heart Failure (2.2) 40 mg twice daily 40-160 mg twice daily 160 mg twice daily Post-Myocardial Infarction (2.3) 20 mg twice daily 20-160 mg twice daily 160 mg twice daily * as tolerated by patient No initial dosage adjustment is required for elderly patients, for patients with mild or moderate renal impairment, or for patients with mild or moderate liver insufficiency. Care should be exercised with dosing of Diovan in patients with hepatic or severe renal impairment. Diovan may be administered with or without food. In heart failure patients, consideration should be given to reducing the dose of concomitant diuretics. Following myocardial infarction, consideration should be given to a dosage reduction if symptomatic hypotension or renal dysfunction occurs. |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021283s027lbl.pdf |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Research Highlight |